Why the study?
Do ACE inhibitors (captopril, enalapril, quinapril) have favorable pharmacokinetics, efficacy, and safety profiles in young and elderly patients with hypertension?
Do ACE inhibitors (captopril, enalapril, quinapril) have favorable pharmacokinetics, efficacy, and safety profiles in young and elderly patients with hypertension?
ACE inhibitors, particularly quinapril, are effective and well-tolerated for the treatment of hypertension in both young and elderly patients.
Quinapril may warrant consideration for tolerability in hypertension across ages; leaves open need for prospective head-to-head trials.
As the population with hypertension becomes older, it is important to determine the properties of angiotensin-converting enzyme (ACE) inhibitors in the elderly. The pharmacokinetics and efficacy of captopril, enalapril, and a new once-daily ACE inhibitor, quinapril for the treatment of hypertension in young and elderly patients are reviewed, and the safety profiles of these agents in young and elderly patients are discussed. Although the safely profile of all three drugs is very favorable, quinapril tended to be better tolerated by patients of all ages in comparative clinical trials.
No takes yet. Share an insight, caveat, or question.
Posvar et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: